GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Insider Ownership

NeoImmuneTech (XKRX:950220) Insider Ownership : 0.00 % (As of May. 28, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NeoImmuneTech's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NeoImmuneTech's Institutional Ownership is 0.21%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NeoImmuneTech's Float Percentage Of Total Shares Outstanding is 0.00%.


NeoImmuneTech Insider Ownership Historical Data

The historical data trend for NeoImmuneTech's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech Insider Ownership Chart

NeoImmuneTech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Insider Ownership
- - - - -

NeoImmuneTech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NeoImmuneTech Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


NeoImmuneTech (XKRX:950220) Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech (XKRX:950220) Headlines

No Headlines